Patents by Inventor Mark Jeroen KWAKKENBOS

Mark Jeroen KWAKKENBOS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20200325213
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 15, 2020
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • RSV-specific binding molecules and means for producing them
    Patent number: 10730931
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 4, 2020
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • EX VIVO ANTIBODY PRODUCTION
    Publication number: 20200149007
    Abstract: The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
    Type: Application
    Filed: September 19, 2019
    Publication date: May 14, 2020
    Inventors: PAULA MARIA WILHELMINA VAN HELDEN, Mark Jeroen KWAKKENBOS, Hergen Spits, Tim Beaumont
  • Means and methods for producing stable antibodies
    Patent number: 10611829
    Abstract: The invention provides means and methods for selecting and producing stable antibodies against an antigen of interest, using stable ex vivo B cell cultures.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: April 7, 2020
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Mark Jeroen Kwakkenbos, Koen Wagner, Adrianus Quirinus Bakker
  • Means and methods for producing high affinity antibodies
    Patent number: 10344076
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 9, 2019
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20180327484
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: July 23, 2018
    Publication date: November 15, 2018
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20180292391
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: February 20, 2018
    Publication date: October 11, 2018
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • RSV-specific binding molecules and means for producing them
    Patent number: 10059757
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: August 28, 2018
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Means and methods for producing high affinity antibodies
    Patent number: 9969795
    Abstract: The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: May 15, 2018
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker, Koen Wagner
  • Gram-positive bacteria specific binding compounds
    Patent number: 9927428
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: March 27, 2018
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • INFLUENZA A VIRUS SPECIFIC ANTIBODIES
    Publication number: 20170313766
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 2, 2017
    Inventors: Hergen SPITS, Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Arjen Quirinus BAKKER
  • Influenza A virus specific antibodies
    Patent number: 9718874
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: August 1, 2017
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker
  • Gram-positive bacteria specific binding compounds
    Patent number: 9688745
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: June 27, 2017
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20170067880
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: August 24, 2016
    Publication date: March 9, 2017
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • EX VIVO ANTIBODY PRODUCTION
    Publication number: 20170009205
    Abstract: The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
    Type: Application
    Filed: December 24, 2014
    Publication date: January 12, 2017
    Inventors: Pauline Maria Wilhelmina VAN HELDEN, Mark Jeroen KWAKKENBOS, Hergen SPITS, Tim BEAUMONT
  • MEANS AND METHODS FOR PRODUCING STABLE ANTIBODIES
    Publication number: 20170008952
    Abstract: The invention provides means and methods for selecting and producing stable antibodies against an antigen of interest, using stable ex vivo B cell cultures.
    Type: Application
    Filed: January 30, 2015
    Publication date: January 12, 2017
    Inventors: Mark Jeroen KWAKKENBOS, Koen WAGNER, Adrianus Quirinus BAKKER
  • Gram-positive bacteria specific binding compounds
    Patent number: 9458228
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: October 4, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20160244509
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: February 18, 2016
    Publication date: August 25, 2016
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20160222096
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: December 28, 2015
    Publication date: August 4, 2016
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L.W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Gram-positive bacteria specific binding compounds
    Patent number: 9399673
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 26, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia